{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"73.7"},{"groupId":"OG003","value":"43.5"},{"groupId":"OG004","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Based on investigator review of radiographic images according to iRECIST. Clinical benefit rate according to iRECIST was defined as the percentage of patients with partial responses, complete responses, and stable disease according to iRECIST for target lesions and assessed by CT/MRI.","groups":[{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.","id":"OG000","title":"Part A (Nanrilkefusp Alfa Monotherapy)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle twice a day as 2 divided doses (50%:50%) with the second dose on each treatment day administered 8 hours (±15 min) after the first dose.","id":"OG001","title":"Part A1 (Nanrilkefusp Alfa Divided Dosing, Monotherapy)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.\n\nPembrolizumab 200 mg was administered intravenously on day 1 of the 21-day treatment cycle.","id":"OG002","title":"Part B (Nanrilkefusp Alfa Combined With Pembrolizumab)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.","id":"OG003","title":"Part D (Nanrilkefusp Alfa Monotherapy, Expansion at the RP2D Identified in Part A)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle twice a day as 2 divided doses (50%:50%) with the second dose on each treatment day administered 8 hours (±15 min) after the first dose. Pembrolizumab 200 mg was administered intravenously on day 1 of the 21-day treatment cycle.","id":"OG004","title":"Part B1 (Nanrilkefusp Alfa Twice Daily With Pembrolizumab, Expansion at RP2D Identified in Part A)"}],"paramType":"NUMBER","populationDescription":"In the trial protocol and SAP it was pre-specified that the arms in individual trial parts will be analyzed combined (A, A1, B, D, and B1).","reportingStatus":"POSTED","timeFrame":"Day 1 up to approximately 5 years 5 months","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}